Comparative Pharmacology
Head-to-head clinical analysis: CYTARABINE versus FLOXURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTARABINE versus FLOXURIDINE.
CYTARABINE vs FLOXURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. It is converted intracellularly to its active triphosphate form, which competes with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase. It also inhibits DNA repair and RNA synthesis.
FLOXURIDINE is an antimetabolite that inhibits thymidylate synthetase, thereby blocking DNA synthesis. It is converted to 5-fluorouracil (5-FU) in the body, which is further metabolized to active nucleotides that incorporate into RNA and inhibit thymidylate synthase.
100-200 mg/m² IV continuous infusion over 24 hours for 7 days (induction) or 1-3 g/m² IV every 12 hours for 3-6 days (high-dose). Intrathecal: 30-100 mg/m² (max 100 mg) once every 2-7 days.
0.1 to 0.6 mg/kg/day via continuous intra-arterial infusion for 14 days, then 7-day rest; typical dose 0.3 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateCytarabine + Digoxin
"Cytarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFloxuridine + Digoxin
"Floxuridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCytarabine + Digitoxin
"Cytarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFloxuridine + Digitoxin
"Floxuridine may decrease the cardiotoxic activities of Digitoxin."
Initial distribution half-life ~10 min; terminal elimination half-life ~1-3 hours (biphasic); prolongs in renal impairment.
Terminal half-life is approximately 20 minutes; clinical context: rapid clearance necessitates continuous IV infusion for sustained antineoplastic effect.
Primarily hepatic metabolism (deaminated by cytidine deaminase to inactive uracil arabinoside); renal excretion of unchanged drug accounts for <10% of dose; <1% biliary/fecal.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for <10% of unchanged drug; biliary/fecal excretion is minor.
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite